Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2019/11/01
-
Journal
-
Indian UGC (journal)
-
Refrences59
-
Citations91
-
Brian Barry
-
April A. Erwin
-
Jessica Stevens
-
Carlo Tornatore
Cite
Barry, Brian, et al. “Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations”. Neurology and Therapy, vol. 8, no. 2, 2019, pp. 241-50, https://doi.org/10.1007/s40120-019-00160-9.
Barry, B., Erwin, A. A., Stevens, J., & Tornatore, C. (2019). Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations. Neurology and Therapy, 8(2), 241-250. https://doi.org/10.1007/s40120-019-00160-9
Barry B, Erwin AA, Stevens J, Tornatore C. Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations. Neurology and Therapy. 2019;8(2):241-50.
Journal Categories
Medicine
Internal medicine
Neurosciences
Biological psychiatry
Neuropsychiatry
Neurology
Diseases of the nervous system
Medicine
Medicine (General)
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| 10.1212/NXI.0000000000000566 | Neurology Neuroimmunology & Neuroinflammation |
| 2019 | |
| Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis | Internal Medicine |
| 25 | 2018 |
Clinical activity after fingolimod cessation: disease reactivation or rebound? | European Journal of Neurology |
| 52 | 2018 |
Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis | Multiple Sclerosis Journal |
| 35 | 2018 |
Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation | Multiple Sclerosis Journal |
| 29 | 2018 |
Refrences Analysis
The category
Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry 45
is the most frequently represented among the references in this article. It primarily includes studies from Journal of Neurology The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Neutrophil Membrane‐Camouflaged Polyprodrug Nanomedicine for Inflammation Suppression in Ischemic Stroke Therapy | Advanced Materials |
| 2024 | |
| A case of early disease rebound after fingolimod discontinuation in a patient with multiple sclerosis and SARS-CoV-2 infection | Neurological Sciences |
| 2024 | |
| Sensitive, reliable and simultaneous determination of Fingolimod and Citalopram drug molecules used in multiple sclerosis treatment based on magnetic solid phase extraction and HPLC-PDA | Journal of Chromatography B |
| 2024 | |
| Frequency and risk factors of rebound after fingolimod discontinuation – A retrospective study | Multiple Sclerosis and Related Disorders |
| 1 | 2024 |
| Highly Effective Therapy Versus Escalation Approaches in Early Multiple Sclerosis | Neurologic Clinics |
| 2 | 2024 |
Citations Analysis
The category
Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry: Neurology. Diseases of the nervous system 59
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled The Impact of Immunosuppression and Autoimmune Disease on Severe Outcomes in Patients Hospitalized with COVID-19 and was published in 2020. The most recent citation comes from a 2024 study titled Treatment algorithms of relapsing multiple sclerosis: an exploration based on the available disease-modifying therapies in China. This article reached its peak citation in 2021, with 24 citations. It has been cited in 53 different journals, 24% of which are open access. Among related journals, the Multiple Sclerosis and Related Disorders cited this research the most, with 18 citations. The chart below illustrates the annual citation trends for this article.